CD44‐Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid‐Coated Polymersomes for Synergistic Anti‐Inflammatory Therapy
ChemMedChem · 2026-07-29 · 21 (14)
DOI: 10.1002/cmdc.70396 ↗At a glance
Journal article in ChemMedChem, published online on 2026-07-23. Written by Youngheun Cho and 5 co-authors. Institution: Department of Chemical and Biomolecular Engineering, Sogang University, Seoul, Republic of Korea. Major MEDLINE topics: Celecoxib, Hyaluronan Receptors, Hyaluronic Acid, Melitten. 39 references. The full text is freely available in PubMed Central. Funded by: Ministry of Education, Science, and Technology, Republic of Korea and the Ministry of Food and Drug Safety grant, Republic of Korea.
Abstract (original language)
Activated macrophages are key effector cells in inflammatory diseases, but the therapeutic use of membrane‐active agents such as melittin (MEL) is limited by nonspecific cytotoxicity and hemolysis. Here, we developed a hyaluronic acid (HA)‐coated MEL‐based polymersome (PMHA) for CD44‐targeted codelivery of MEL and celecoxib (CXB). MEL was incorporated into the vesicular membrane, whereas CXB was loaded into the hydrophobic domain. PMHA showed a hydrodynamic diameter of 265.5 ± 1.6 nm, a zeta‐potential of −21.14 ± 1.1 mV, a CXB encapsulation efficiency of 70.81 ± 4.18%, and a drug loading capacity of 12.87 ± 1.92%. In lipopolysaccharide (LPS)‐stimulated RAW 264.7 macrophages, anti‐CD44 antibody blocking reduced Alexa Fluor 647‐labeled PMHA uptake by approximately 37.5%, supporting HA–CD44‐mediated internalization. PMHA reduced MEL‐associated cytotoxicity and hemolytic activity and enabled pH‐responsive CXB release. Codelivery of MEL and CXB suppressed cyclooxygenase‐2 (COX‐2) and tumor necrosis factor‐α (TNF‐α) expression, with combination index (CI) values of 0.48 and 0.67, respectively. These findings support further evaluation of PMHA as a macrophage‐targeted anti‐inflammatory nanoplatform.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Chemical and Biomolecular Engineering, Sogang University, Seoul, Republic of Korea.
- Department of Biomedical Engineering, Sogang University, Seoul, Republic of Korea.
Funding
- Ministry of Education, Science, and Technology
- Republic of Korea and the Ministry of Food and Drug Safety grant
- Republic of Korea
- Ministry of Education, Science and Technology
Cite
APA
Cho, Y., Kim, J., Moon, J., Nam, S., Kim, J., & Kim, H. (2026). CD44‐Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid‐Coated Polymersomes for Synergistic Anti‐Inflammatory Therapy. ChemMedChem, 21(14). https://doi.org/10.1002/cmdc.70396
Vancouver
Cho Y, Kim J, Moon J, Nam S, Kim J, Kim H. CD44‐Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid‐Coated Polymersomes for Synergistic Anti‐Inflammatory Therapy. ChemMedChem. 2026;21(14). doi:10.1002/cmdc.70396
BibTeX
@article{Cho2026,
author = {Cho, Youngheun and Kim, Junmin and Moon, Jooho and Nam, Soobin and Kim, Junhyung and Kim, Hyuncheol},
title = {CD44‐Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid‐Coated Polymersomes for Synergistic Anti‐Inflammatory Therapy},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {14},
doi = {10.1002/cmdc.70396}
}
EUVIMED